Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01043393 · ClinicalTrials.gov registry record · Phase 2
Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study
A Phase 2 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01043393 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 24 participants.
The verdict
NCT01043393, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the potential of desoximetasone 0.25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone 0.25% Topical Spray in patients with moderate to severe plaque psoriasis. The secondary objectives are to evaluate the efficacy parameters and to evaluate the adverse event (AE) profile.
Interventions
- DRUG Desoximetasone 0.25% spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01043393
The ClinicalTrials.gov registry entry for NCT01043393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Desoximetasone 0.25% spray is the first listed.
NCT01043393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01043393 about?
NCT01043393 is a clinical study titled "Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study". The objective of this study is to evaluate the potential of desoximetasone 0.25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone 0.25% Topical Spray in patients with moderate to severe plaque psoriasis....
What is the current status of trial NCT01043393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01043393?
The interventions under investigation include: Desoximetasone 0.25% spray (DRUG).
Who is sponsoring clinical trial NCT01043393?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.